home / stock / adms / adms news

ADMS News and Press, Adamas Pharmaceuticals Inc. From 10/08/18

Stock Information
Company Name: Adamas Pharmaceuticals Inc.
Stock Symbol: ADMS
Market: NASDAQ
Website: adamaspharma.com
Menu
ADMS ADMS Quote ADMS Short ADMS News ADMS Articles ADMS Message Board
Get ADMS Alerts

News, Short Squeeze, Breakout and More Instantly...
ADMS - Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI(TM) in Parkinson's Disease Patients with Dyskinesia

GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two years Results show a comparable 35% reduction from baseline in dyskinesia and OFF was achieved across all subgroups naïve to GOCOVRI as measured by MDS-UPDRS, Pa...
ADMS - Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted nine new employees the option to purchase an aggregate of 49,210 shares of the company’...

ADMS - Premarket analyst action - healthcare

Natera (NASDAQ: NTRA ) initiated with Neutral rating and $26 (11% upside) price target at JPMorgan. More news on: Natera, Evolent Health, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, , Read more ...

ADMS - Adamas Announces Publication of Data Demonstrating Dyskinesia's Impact on Activities of Daily Living in People with Parkinson's Disease

EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) ...
Previous 10 Next 10